hero section gradient
17 handpicked stocks

Samsung AI Chip Expansion Suppliers to Watch in 2025

Samsung is significantly increasing its chip production to meet surging demand from the artificial intelligence industry. This major investment is poised to benefit the suppliers and manufacturers of specialized semiconductor equipment and materials required for the expansion.

Author avatar

Han Tan | Market Analyst

Published on November 17

Your Basket's Financial Footprint

This basket has a total market capitalisation of $2.04T and is heavily anchored by a few very large-cap constituents, creating a predominantly large-cap profile that generally suggests greater stability.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and closer tracking to broader market trends, reducing idiosyncratic risk.
  • Better suited as a core, diversified holding rather than a short-term speculative position.
  • Expect steady long-term appreciation rather than rapid, explosive gains; growth may be gradual.
Total Market Cap
  • TSM: $1.19T

  • ASML: $394.62B

  • LRCX: $186.22B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Samsung's multi-billion dollar investment into new AI chip production creates a ripple effect throughout the semiconductor supply chain. As the tech giant builds new facilities, companies providing essential equipment, materials, and services are positioned to benefit from this massive capital expenditure cycle.

2

What You Need to Know

This group focuses on the critical ecosystem behind chip manufacturing - from lithography equipment to specialty chemicals. These aren't the chip makers themselves, but the companies that make chip production possible. Mass production begins in 2028, creating a multi-year opportunity.

3

Why These Stocks

Each company was selected for its direct role in the semiconductor manufacturing process. From ASML's photolithography systems to Entegris's advanced materials, these firms form the backbone of the supply chain that Samsung will rely on for its expansion.

Why You'll Want to Watch These Stocks

🚀

Multi-Year Growth Cycle

Samsung's expansion runs through 2028, creating a sustained demand cycle for equipment and materials suppliers that could drive years of growth.

🤖

AI Boom Beneficiaries

These companies are positioned at the heart of the AI revolution, supplying the critical infrastructure needed to manufacture the chips powering artificial intelligence.

Supply Chain Advantage

Whilst everyone focuses on chip makers, these upstream suppliers often see demand spikes first and may benefit from less competition for investor attention.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions